News
GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...
Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...
3d
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...
Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss: Study
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...
Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...
In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...
Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...
British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...
3d
HealthDay on MSNENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy UseIn postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results